Validation of cueStim for Reduction of Freezing of Gait in Parkinson's Disease
The goal of this clinical trial is to learn if the cueStim device can reduce the duration of freezing of gait (FoG) that occurs in patients with Parkinson's Disease. The study will compare two modes of operation of the cueStim device; both modes of operation use the same wearable device. The purpose of the study is to compare how the two modes affect symptoms across study participants. Because this is a research study, it is not yet known whether either mode reduces symptoms.
Participants will:
- Be randomized to one of the two modes available on the cueStim device
- Wear the device for 4 weeks as they go about their daily life
- Complete daily diary entries to document symptoms, falls and overall experience
- Check-in with the clinical site throughout participation
- Complete a final follow-up visit
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a prospective, randomized, double-blind, parallel group, multicenter, pivotal clinical trial to validate the use of cueStim for reduction of duration of FoG in Parkinson's patients.
Enrolled subjects will be randomized 1:1 to two different modes of treatment. All subjects will be blinded to the study hypothesis. The clinician will not be blinded; however, specialists who will evaluate the outcome will be blinded. Enrolled subjects will be provided with training on the device during a clinic visit, and phone support is available throughout the home treatment duration.
Study procedures / visits consists of:
- In-clinic Screening visit to ensure eligibility
- Baseline visit for device setup and training (may be combined with screening visit)
- "Home" (unsupervised at and out of the home) use of the device for four (4) weeks) as the patient goes about their daily life
- End-of-treatment Follow-up visit
The primary objective of this clinical investigation is to determine if one mode of treatment demonstrates superiority after four weeks of device use, in reducing the duration of FoG, while the device is being worn by patients with PD receiving medication.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
Florida
-
Boca Raton, Florida, États-Unis, 33486
- Parkinson's Disease and Movement Disorders Center of Boca Raton
-
Chercheur principal:
- Stuart Isaacson, MD
-
Contact:
- Research Coordinator
- Numéro de téléphone: 2 561-392-1818
- E-mail: info@ParkinsonsCenter.org
-
Daytona Beach, Florida, États-Unis, 32117
- Arrow Clinical Trials
-
Chercheur principal:
- David Billmeier, MD
-
Contact:
- Lexi Bancroft
- Numéro de téléphone: 0307 (386) 278-8000
- E-mail: ABancroft@arrowtrials.com
-
-
Georgia
-
Atlanta, Georgia, États-Unis, 30329
- Emory University
-
Contact:
- Lucas McKay, PhD MSCR
- Numéro de téléphone: 404-550-5157
- E-mail: j.lucas.mckay@emory.edu
-
Chercheur principal:
- Lucas McKay, PhD MSCR
-
-
Kansas
-
Kansas City, Kansas, États-Unis, 66160
- University of Kansas
-
Contact:
- Kelly Lyons, PhD
- Numéro de téléphone: 913-588-7159
- E-mail: klyons@kumc.edu
-
Chercheur principal:
- Kelvin Au, MD, FRCPC
-
-
Oregon
-
Portland, Oregon, États-Unis, 97239
- Oregon Health and Science University
-
Chercheur principal:
- Martina Mancini, PhD
-
Contact:
- Graham Harker, MPH
- Numéro de téléphone: (503) 418-2601
- E-mail: balance@ohsu.edu
-
-
Washington
-
Kirkland, Washington, États-Unis, 98034
- Evergreen Health Research Program
-
Chercheur principal:
- Pinky Agarwal, MD, FAAN
-
Contact:
- Evergreen Health
- Numéro de téléphone: 425-899-5385
- E-mail: evergreenresearch@evergreenhealthcare.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Age 60-90 years, inclusive
- Diagnosis of idiopathic PD, confirmed by a neurologist/Medical Doctor (MD), medical records, and verified during a post consent in-clinic evaluation by a trained MD
- Patients can walk 12 meters without a walking aid (cane permitted during daily life)
- The patient is using levodopa treatment. PD medications are stable, with no changes in PD-related medications for at least four weeks prior to screening visit, and stable dosing expected for duration of the study
- Score greater or equal to 22 on the Montreal Cognitive Assessment (MoCA)
- Satisfactory standard neurological examination, including completion of MDS- UPDRS I, II, III and IV by study clinician
- PTF ≥20% during the baseline in-clinic FoG Provocation Test (conducted without the device) as determined by the centralized blinded video analysis using the FoG Switch tool by trained personnel independent of site investigators.
Exclusion Criteria
- Atypical or secondary parkinsonism, including vascular parkinsonism
- History of dementia, severe depression, psychosis, or active hallucinations
- History of migraines, tinnitus, seizures or sensory issues
- Other neurological or orthopedic impairment significantly affecting gait
- Previous use of cueing devices within the last 3 months
- Use of implanted electronic devices, including deep brain stimulation (DBS)
- Use of assistive devices incompatible with the device (DBS users will be excluded
- Is participating in another clinical trial during the study period
- Any condition that, in the investigator's opinion, makes the participant unsuitable
- As per medical records, any of the following identified within 3 months: myocardial infarction, hospitalization for unstable angina, stroke, coronary artery bypass graft, percutaneous coronary intervention, implantation or use of a cardiac resynchronization therapy device, active treatment for cancer or other malignant disease, uncontrolled congestive heart disease (NYHA class >3), acute psychosis or major psychiatric disorders or continued substance abuse.
- Pregnant or breastfeeding women
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: First mode of cueStim
The first, unidentified mode delivers electrical stimulation to the legs to improve gait (i.e., reduce Freezing of Gait [FoG]) of patients with Parkinson's disease (PD). There are also 2 electrodes which connect the stimulators to the subject. Stimulators are attached to the thigh of each leg. The stimulators deliver sensory electrical stimulation (sES), a non-adaptive rhythmic cueing strategy consisting of a continuous series of biphasic electrical stimulation bursts, in an alternating rhythmic manner scaled to the patient's stride rate. Stimulation is customized to each patient prior to first-time use via a Clinician Tablet Controller. The Tablet Controller is used to program and to adjust device stimulation settings over time. The Stimulators' on-board electronics sense when the patient is sitting, has stopped walking or is attempting to walk and delivers stimulation only when the patient is actively walking or attempting to walk. |
Enrolled patients will be assigned to one of two modes and will be blinded to their assignment.
The Device will be worn for four weeks throughout the patient's daily life.
The patient will complete daily diary entries, periodically check in with the clinical staff, and complete questionnaires related to the impact of freezing of gait and Parkinson's Disease on daily life and function.
|
|
Comparateur actif: Second mode of cueStim
The second, unidentified mode is a modified version of the cueStim stimulator which uses a different mode of stimulation.
|
Enrolled patients will be assigned to one of two modes and will be blinded to their assignment.
The Device will be worn for four weeks throughout the patient's daily life.
The patient will complete daily diary entries, periodically check in with the clinical staff, and complete questionnaires related to the impact of freezing of gait and Parkinson's Disease on daily life and function.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Demonstrate Superiority
Délai: From enrollment to the end of treatment at 4 weeks
|
The main goal of this study is to determine whether one mode of the cueStim device works better than another.
After four weeks of use, it will be compared how well each mode reduces the duration of freezing of gait in patients with Parkinson's Disease who are taking medication, while they are wearing the device.
|
From enrollment to the end of treatment at 4 weeks
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- cueStim-PD
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .